Department of Radiation Oncology, University of Texas M. D. Anderson Cancer Center, Houston, TX 77030-4009, USA.
Int J Radiat Oncol Biol Phys. 2010 Dec 1;78(5):1356-65. doi: 10.1016/j.ijrobp.2009.10.002. Epub 2010 Jun 18.
To investigate long-term swallowing function in oropharyngeal cancer patients treated with intensity-modulated radiotherapy (IMRT), and to identify novel dose-limiting criteria predictive for dysphagia.
Thirty-one patients with Stage IV oropharyngeal squamous carcinoma enrolled on a Phase II trial were prospectively evaluated by modified barium swallow studies at baseline, and 6, 12, and 24 months post-IMRT treatment. Candidate dysphagia-associated organs at risk were retrospectively contoured into original treatment plans. Twenty-one (68%) cases were base of tongue and 10 (32%) were tonsil. Stage distribution was T1 (12 patients), T2 (10), T3 (4), T4 (2), and TX (3), and N2 (24), N3 (5), and NX (2). Median age was 52.8 years (range, 42-78 years). Thirteen patients (42%) received concurrent chemotherapy during IMRT. Thirteen (42%) were former smokers. Mean dose to glottic larynx for the cohort was limited to 18 Gy (range, 6-39 Gy) by matching IMRT to conventional low-neck fields.
Dose-volume constraints (V30 < 65% and V35 < 35% for anterior oral cavity and V55 < 80% and V65 < 30% for high superior pharyngeal constrictors) predictive for objective swallowing dysfunction were identified by univariate and multivariate analyses. Aspiration and feeding tube dependence were observed in only 1 patient at 24 months.
In the context of glottic laryngeal shielding, we describe candidate oral cavity and superior pharyngeal constrictor organs at risk and dose-volume constraints associated with preserved long-term swallowing function; these constraints are currently undergoing prospective validation. Strict protection of the glottic larynx via beam-split IMRT techniques promises to make chronic aspiration an uncommon outcome.
研究调强放疗(IMRT)治疗的口咽癌患者的长期吞咽功能,并确定新的与吞咽困难相关的剂量限制标准。
31 例 IV 期口咽鳞癌患者入组一项 II 期临床试验,在 IMRT 治疗前、治疗后 6、12 和 24 个月进行改良钡餐吞咽研究。将候选的与吞咽困难相关的危及器官在原始治疗计划中进行回顾性勾画。21 例(68%)为舌根,10 例(32%)为扁桃体。分期分布为 T1(12 例)、T2(10 例)、T3(4 例)、T4(2 例)和 TX(3 例),N2(24 例)、N3(5 例)和 NX(2 例)。中位年龄为 52.8 岁(范围,42-78 岁)。13 例(42%)患者在 IMRT 期间接受同期化疗。13 例(42%)为既往吸烟者。由于匹配 IMRT 到常规低颈野,声门的平均剂量限制在 18 Gy(范围,6-39 Gy)。
通过单因素和多因素分析,确定了预测客观吞咽功能障碍的剂量-体积限制(前口腔 V30<65%和 V35<35%,高咽缩肌 V55<80%和 V65<30%)。仅 1 例患者在 24 个月时出现吸入和置管依赖。
在保护声门的情况下,我们描述了候选的口腔和咽上缩肌危及器官以及与长期吞咽功能保留相关的剂量-体积限制;这些限制目前正在进行前瞻性验证。通过分割 IMRT 技术严格保护声门有望使慢性吸入成为一种罕见的结果。